scholarly journals Novel Pharmacological and Magnetic Resonance Strategies to Enhance Boron Neutron Capture Therapy (BNCT) Efficacy in the Clinical Treatment of Malignant Glioma

10.5772/24756 ◽  
2011 ◽  
Author(s):  
Paola Porcari ◽  
Silvia Capuani ◽  
Francesco Saverio
Keyword(s):  
Magnetic Resonance ◽  
Malignant Glioma ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Clinical Treatment ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture

scholarly journals Boron Neutron Capture Therapy and Add-on Bevacizumab in Patients with Recurrent Malignant Glioma

2021 ◽  
Author(s):  
Motomasa Furuse ◽  
Shinji Kawabata ◽  
Masahiko Wanibuchi ◽  
Hiroyuki Shiba ◽  
Koji Takeuchi ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Boron Neutron Capture Therapy ◽  
Survival Data ◽  
Neutron Capture ◽  
Radiation Necrosis ◽  
Neutron Capture Therapy ◽  
Recurrent Malignant Glioma ◽  
Primary Glioblastoma ◽  
Boron Neutron Capture ◽  
Grade 3

Abstract Introduction: Boron neutron capture therapy (BNCT) has shown excellent survival data but increases in radiation necrosis against recurrent malignant glioma (MG) in previous studies. We proposed that bevacizumab may reduce radiation injury from BNCT by re-irradiation. We evaluated the efficacy and safety of a combination therapy of BNCT and add-on bevacizumab in patients with recurrent MG.Methods: Patients with recurrent MG were treated with reactor-based BNCT. Treatment with bevacizumab (10 mg/kg) was initiated 1–4 weeks after BNCT irradiation and was re-administered every 2–3 weeks until disease progression. Initially diagnosed glioblastomas were categorized as primary glioblastoma (pGBM) and other forms of MG were categorized as non-pGBM. Results: Twenty-five patients (14 with pGBM and 11 with non-pGBM) were treated with BNCT and add-on bevacizumab. The 1-year survival rate for pGBM and non-pGBM was 63.5% (95% CI, 33.1–83.0) and 81.8% (95%CI, 44.7–95.1), respectively. The median OS was 21.4 months (95% CI, 7.0–36.7) and 73.6 months (95% CI, 11.4–77.2) for pGBM and non-pGBM, respectively (p = 0.0428). The median PFS was 8.3 months (95%CI, 4.2–12.1) and 15.6 months (95% CI, 3.1–29.8) for pGBM and non-pGBM, respectively (p = 0.0207). Alopecia occurred in all patients. Six patients experienced adverse events ≥ grade 3.Conclusions: BNCT and add-on bevacizumab were found to provide both a long OS and a long PFS, compared to the previous studies of BNCT alone for recurrent MG. The add-on bevacizumab may reduce the detrimental effects of BNCT radiation, including pseudoprogression and radiation necrosis.

Sign in / Sign up

Export Citation Format

Share Document